Graves' Disease: History and Discovery

Graves' disease — the autoimmune overactivity of the thyroid that produces a swollen neck, a racing heart, and, most strikingly, eyes that bulge from their sockets — carries one of medicine's most famously disputed names. The Irish physician Robert James Graves described it in his Dublin clinical lectures in 1835, and the English-speaking world has honoured him ever since. Yet the bath physician Caleb Hillier Parry had recorded the same picture in 1786 (published only after his death, in 1825), the Italian Giuseppe Flajani had noted it in 1802, and the German Karl Adolph von Basedow described it independently in 1840 — which is why most of continental Europe still calls it Basedow's disease. The true cause — a rogue antibody that switches the thyroid on and will not switch it off — was not identified until Adams and Purves found it in 1956. This is the story of how a cluster of dramatic symptoms became a named disease, and of how that name became a century-long question of priority and geography.

Table of Contents

  1. Parry, Flajani, and the Earliest Cases
  2. Robert Graves and the 1835 Description
  3. Von Basedow and the Merseburg Triad (1840)
  4. Graves vs. Basedow: A Question of Geography
  5. Discovering the Autoimmune Cause (1956)
  6. A History of Diagnosis and Treatment
  7. Modern Understanding
  8. Research Papers and References
  9. Connections

Parry, Flajani, and the Earliest Cases

The combination of an enlarged thyroid, a pounding heart, and protruding eyes is so dramatic that it is hard to believe physicians had not always recognised it. Yet a single, named description of the full syndrome does not appear in the historical record until the late eighteenth century. The first person generally credited with observing it is Caleb Hillier Parry (1755–1822), a respected physician of Bath, England, and a friend of Edward Jenner. Parry recorded a case as early as 1786 — a woman with a swollen thyroid whose heart palpitations and bulging eyes he carefully noted — but he did not publish it in his lifetime. His observations appeared only posthumously, gathered by his son and printed in 1825 under the title Enlargement of the Thyroid Gland in Connection with Enlargement or Palpitation of the Heart, a full decade before Graves spoke in Dublin.

Parry was not entirely alone among the early describers. In 1802 the Italian surgeon Giuseppe Flajani reported cases pairing goitre with palpitations and prominent eyes, and his countryman Antonio Giuseppe Testa recorded similar observations in 1810. These Italian reports circulated little outside their own language and region, and so — like Parry's unpublished notes — they did not fix the syndrome in the wider medical mind. For this reason the condition is sometimes given the full multi-name eponym Flajani–Parry–Graves–von Basedow disease in modern reviews that try to honour everyone who saw it early.

It is worth being precise about what "first" means here. None of these early observers understood what caused the disease, and none gave it a name that stuck; they described a striking cluster of signs in a handful of patients. Priority for the earliest recorded observation belongs to Parry (1786); priority for the earliest publication of the syndrome belongs, by a narrow margin, to Flajani (1802); but priority for the name the English-speaking world uses would fall, half a century later, to a Dublin physician who was not even the first to publish.

Back to Table of Contents

Robert Graves and the 1835 Description

Robert James Graves (1796–1853) was one of the towering figures of nineteenth-century Irish medicine. Educated in Dublin and on the Continent, he became a physician at the Meath Hospital and a reformer of clinical teaching, insisting that students learn at the bedside rather than only from lectures — a method he absorbed in part from German practice. He is also remembered for a famous quip about his bedside approach to fever, suggesting his own epitaph should read, "He fed fevers" — a then-radical idea that sick patients should be nourished rather than starved.

In 1835, in the course of his clinical lectures, Graves described a small group of patients — classically given as three young women — who shared violent, long-standing palpitations of the heart together with enlargement of the thyroid gland. His account, published that year in the London Medical and Surgical Journal, drew the connection between the racing heart and the swollen neck, and he noted the predominance of the condition in women. A fourth case, with the marked eye protrusion (exophthalmos) that would become the syndrome's signature, is associated with his Dublin colleague William Stokes. The condition came to be called exophthalmic goitre, and in the English-speaking world, Graves' disease.

Graves' description was lucid, was published in a journal read across the anglophone medical world, and was made by a physician of genuine eminence whose lectures were widely reprinted. Those facts — clarity, reach, and reputation — matter enormously to how an eponym is born. They explain why a man who came after Parry, Flajani, and Testa nonetheless became the name attached to the disease throughout Britain, Ireland, North America, and the wider English-speaking world.

Back to Table of Contents

Von Basedow and the Merseburg Triad (1840)

Five years after Graves spoke in Dublin, and apparently without knowledge of his work, a general practitioner in the small Prussian town of Merseburg published his own careful account of the same disease. Karl Adolph von Basedow (1799–1854) — his first name is also rendered Carl — was not a famous professor but a keen-eyed family doctor who had followed several patients for years. In 1840 he published a paper whose German title translates roughly as Exophthalmos due to hypertrophy of the cellular tissue in the orbit, describing four patients in whom three signs reliably appeared together.

Those three signs — goitre (the swollen thyroid), exophthalmos (the protruding eyes), and palpitations (the racing heart) — became known as the Merseburg triad, after Basedow's town. The triad is a genuinely useful clinical shorthand, and Basedow's description was so vivid and complete that German-speaking medicine adopted his name for the condition almost immediately. Across the German-speaking world and much of continental Europe, the disease has been called Morbus Basedow (Basedow's disease) ever since.

Basedow's independence from Graves is important to the story. This was not plagiarism or a follow-up; it was a second, parallel discovery of the same natural pattern by a careful observer working in a different country and language. Such independent re-description is common in the history of medicine, and it is precisely what produced the disease's split identity: two honest, capable describers, on two sides of a language barrier, each of whom became the eponym for the readers who could understand him.

Back to Table of Contents

Graves vs. Basedow: A Question of Geography

Why does an American or British doctor say "Graves' disease" while a German or French doctor says "Basedow's disease" for exactly the same condition? The answer is a small, very human episode in the history of naming. The eponym maladie de Graves was promoted by the influential French clinician Armand Trousseau, who in 1862 credited the condition to Graves in his widely studied lectures on clinical medicine. Trousseau's endorsement carried weight, and through it Graves' name spread into the French and English literatures.

From there, the deciding factor was simply the language in which medicine was increasingly published and read. As English became the dominant language of international medical writing, "Graves' disease" travelled with it; as German medicine flourished and named the condition for its own observer, "Basedow's disease" held firm across the Continent. The result is one of the cleanest examples of an eponym divided by geography rather than by evidence: both men described the disease honestly and well, and which name a textbook uses tells you more about where it was written than about who saw the disease first.

The unfairness to Parry did not go unnoticed. In 1898 the great physician Sir William Osler drew attention to Parry's priority and argued that the condition might justly be called Parry's disease. The suggestion was historically sound but came far too late: by the end of the nineteenth century the names Graves and Basedow were too firmly entrenched in their respective halves of the medical world to be displaced. Parry's name survives today only in the long combined eponym used by historians. The honest summary is this — Parry observed it first, Flajani published a description first, Graves and Basedow each made it famous in their own language, and Trousseau handed the English-speaking world its name.

Back to Table of Contents

Discovering the Autoimmune Cause (1956)

For more than a century after Graves and Basedow, physicians could recognise the disease perfectly but could not explain it. They could see the over-driven thyroid; the question was what was doing the driving. The thyroid is normally commanded by a pituitary hormone called thyroid-stimulating hormone (TSH, or thyrotropin), so an early and reasonable hypothesis was that Graves' disease must be caused by too much TSH pouring out of the pituitary gland. That hypothesis was plausible, widely held — and, as it turned out, wrong.

The breakthrough came in 1956 in New Zealand, when Duncan Adams and Herbert Purves studied the blood of patients with Graves' disease and found in it a thyroid-stimulating factor that behaved quite unlike TSH. Where TSH acts quickly and briefly, this mysterious factor went on stimulating the thyroid for many hours — so they named it the long-acting thyroid stimulator, or LATS. Crucially, LATS came not from the pituitary but from the patient's own blood, pointing away from the pituitary-overdrive theory and toward something the body itself was producing in error.

What was LATS? The next decade answered the question. In 1964 investigators including Meek and colleagues and Kriss and colleagues showed that LATS was an immunoglobulin — an antibody, of the IgG class. This reframed Graves' disease entirely: it was an autoimmune disease, in which the immune system mistakenly manufactures an antibody that latches onto the thyroid's TSH receptor and jams it into the "on" position. The thyroid, obeying a false and unrelenting signal, floods the body with hormone. Modern medicine now calls these antibodies thyroid-stimulating immunoglobulins (TSI) or TSH-receptor antibodies (TRAb), and measuring them is part of how Graves' disease is diagnosed today. The 1956 discovery of LATS is the hinge on which the entire modern, autoimmune understanding of the disease turns.

Back to Table of Contents

A History of Diagnosis and Treatment

The treatment of Graves' disease has its own rich history, and for most of it, surgery led the way. Removing part of the overactive thyroid could relieve the disease, but operating on a thyrotoxic patient was dangerous: the surgery itself could trigger a life-threatening "thyroid storm." The turning point came around 1922–1923, when Henry S. Plummer at the Mayo Clinic introduced the use of iodine (Lugol's solution) before surgery. Pharmacological doses of iodine calmed the gland and reduced its blood flow, and surgical mortality at the Mayo Clinic fell dramatically — from several percent to under one percent. Iodine remains a preoperative tool to this day.

The next two revolutions arrived almost together in the 1940s. In early 1941, Saul Hertz — working with the physicist Arthur Roberts and cyclotron-produced radioactive iodine — gave the first therapeutic dose of radioactive iodine (iodine-131) to a patient with Graves' hyperthyroidism. Because the thyroid greedily absorbs iodine, the radioactive form concentrates in the gland and quietly destroys overactive tissue from within, with no incision. Hertz and Roberts published their follow-up series in 1946, and radioiodine became one of the defining therapies of the new field of nuclear medicine — still a mainstay of Graves' treatment today.

The third advance was the antithyroid drug. In 1943 Edwin B. Astwood demonstrated that thiourea and thiouracil could block the thyroid's manufacture of hormone, offering for the first time a way to control the disease with a pill rather than a scalpel or a radioactive isotope. Propylthiouracil followed in 1945 and methimazole (and its prodrug carbimazole) by the end of the decade. These three pillars — antithyroid drugs, radioactive iodine, and surgery — are still the three options a patient with Graves' disease chooses among, and the modern history of the disease is in large part the history of refining and balancing them.

Back to Table of Contents

Modern Understanding

Today Graves' disease is understood as the most common cause of an overactive thyroid, and as a classic autoimmune disorder. The chain of cause and effect that took nearly two centuries to assemble is now textbook: a TSH-receptor antibody (the modern descendant of Adams and Purves' LATS) stimulates the thyroid relentlessly, producing the goitre, the rapid heart, the weight loss, the heat intolerance, the tremor, and the anxiety of thyrotoxicosis. In a subset of patients the same autoimmune process inflames the tissues behind the eyes, producing the exophthalmos that so impressed Parry, Graves, and Basedow — now studied as a distinct entity, thyroid eye disease or Graves' orbitopathy.

Diagnosis has been transformed accordingly. Where the early describers had only their eyes and hands, clinicians now confirm Graves' disease with blood tests measuring thyroid hormones, a suppressed TSH, and the telltale TSH-receptor antibodies, supplemented when needed by radioactive-iodine uptake scans and ultrasound. Treatment still rests on the three twentieth-century pillars — antithyroid drugs, radioiodine, and surgery — with newer biologic therapies now targeting the eye disease specifically. Research continues into what triggers the immune system to turn on the thyroid in the first place, with genetics, stress, infection, and smoking all under study.

The history of Graves' disease is, in the end, a parable about how medicine names and knows things. A vivid pattern was seen, independently, by careful observers in England, Italy, Ireland, and Prussia across half a century; the name that stuck owed as much to language, reputation, and a French clinician's endorsement as to scientific priority; and the disease's true nature stayed hidden until a New Zealand laboratory caught the culprit antibody in 1956. Honouring that history means saying clearly who saw what, and when — and resisting the tidy fiction that any one person simply "discovered" Graves' disease.

Back to Table of Contents

Research Papers and References

The references below combine peer-reviewed historical and clinical literature on Graves' disease with curated PubMed topic-search links. Where a stable DOI or PubMed identifier is available it is given; otherwise the link opens a PubMed topic search at the National Library of Medicine. Primary historical texts (Parry's 1825 posthumous writings, Flajani's 1802 report, Graves' 1835 lecture in the London Medical and Surgical Journal, Basedow's 1840 paper, and Trousseau's 1862 lectures) are named in the article as historical sources rather than as modern citations. Each link opens in a new tab.

  1. Pearce JMS. Robert James Graves (1796–1853) and Graves' disease. — PubMed: Robert James Graves and exophthalmic goitre (history)
  2. A tale of two celts: Caleb Hillier Parry and Robert James Graves. J R Soc Med / history of medicine. — PubMed 19953250: A tale of two celts
  3. Adams DD, Purves HD. Abnormal responses in the assay of thyrotropin (the long-acting thyroid stimulator, LATS). 1956. — PubMed: Adams & Purves, long-acting thyroid stimulator (LATS), 1956
  4. McKenzie JM. The long-acting thyroid stimulator of Graves' disease. Am J Med. 1968;45(5):786–794. — doi:10.1016/0002-9343(68)90077-6
  5. Carl Adolph von Basedow — on the 200th anniversary of his birth (biographical / historical). — PubMed 10355042: Carl Adolph von Basedow biography
  6. Carl Adolph von Basedow — 150th anniversary of his death. — PubMed 15255307: von Basedow, 150th anniversary
  7. Lindholm J, Laurberg P. Hyperthyroidism, exophthalmos, and goiter: historical notes on the orbitopathy. Thyroid. 2010;20(3):291–300. — doi:10.1089/thy.2009.0340
  8. Bartalena L, et al. Autoimmune Thyroid Disease (Flajani–Parry–Graves–von Basedow Disease): etiopathogenesis, clinical manifestations and diagnosis. — doi:10.1007/978-3-319-25871-3_5
  9. Iodine in the therapy of Graves' disease: a century after Henry S. Plummer. — PMC10024581: Iodine therapy a century after Plummer
  10. Hertz S, Roberts A. Radioactive iodine in the study and treatment of hyperthyroidism (history of I-131 therapy). — PubMed: Hertz & Roberts, radioactive iodine in hyperthyroidism
  11. Astwood EB and the development of antithyroid drugs (thiouracil, propylthiouracil, methimazole). — PubMed: Astwood and the antithyroid drugs (history)
  12. Analysis of Graves' disease from the origins to the current historical evolution. Medicina Historica. — PubMed: history of Graves' disease discovery and treatment
  13. Smith TJ, Hegedus L. Graves' disease (modern review). N Engl J Med. 2016;375(16):1552–1565. — doi:10.1056/NEJMra1510030
  14. Thyroid-stimulating immunoglobulins / TSH-receptor antibodies (TRAb) as immunoglobulins — identification of LATS as IgG (Meek, Kriss, 1964). — PubMed: thyroid-stimulating immunoglobulins / TRAb

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents